These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

11157 related articles for article (PubMed ID: 10803718)

  • 1. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Consolidation biochemotherapy for patients with advanced nonsmall cell lung carcinoma responding to induction PVM (cisplatin, vinblastine, mitomycin-C) regimen. A phase II study.
    Tummarello D; Graziano F; Isidori P; Santo A; Cetto G; Fedeli A; Rossi G; Cellerino R
    Cancer; 1996 Jun; 77(11):2251-7. PubMed ID: 8635092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.
    Legha SS; Ring S; Eton O; Bedikian A; Buzaid AC; Plager C; Papadopoulos N
    J Clin Oncol; 1998 May; 16(5):1752-9. PubMed ID: 9586888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
    Gibbs P; Anderson C; Pearlman N; LaClaire S; Becker M; Gatlin K; O'Driscoll M; Stephens J; Gonzalez R
    Cancer; 2002 Jan; 94(2):470-6. PubMed ID: 11900232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha.
    Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N
    Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.
    McDermott DF; Mier JW; Lawrence DP; van den Brink MR; Clancy MA; Rubin KM; Atkins MB
    Clin Cancer Res; 2000 Jun; 6(6):2201-8. PubMed ID: 10873069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biochemotherapy in the treatment of metastatic melanoma in selected patients.
    González Astorga B; Jiménez Rubiano B; Delgado Pérez JR; Valdivia Bautista J; Sánchez Toro C; González Flores E; Luque Caro R; Castellón Rubio V
    Clin Transl Oncol; 2009 Jun; 11(6):382-6. PubMed ID: 19531453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.
    Atkins MB; Gollob JA; Sosman JA; McDermott DF; Tutin L; Sorokin P; Parker RA; Mier JW
    Clin Cancer Res; 2002 Oct; 8(10):3075-81. PubMed ID: 12374674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.
    Eton O; Legha SS; Bedikian AY; Lee JJ; Buzaid AC; Hodges C; Ring SE; Papadopoulos NE; Plager C; East MJ; Zhan F; Benjamin RS
    J Clin Oncol; 2002 Apr; 20(8):2045-52. PubMed ID: 11956264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.
    Flaherty LE; Atkins M; Sosman J; Weiss G; Clark JI; Margolin K; Dutcher J; Gordon MS; Lotze M; Mier J; Sorokin P; Fisher RI; Appel C; Du W
    J Clin Oncol; 2001 Jul; 19(13):3194-202. PubMed ID: 11432886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
    Kirchner HH; Atzpodien J; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biochemotherapy with temozolomide, cisplatin, vinblastine, subcutaneous interleukin-2 and interferon-alpha in patients with metastatic melanoma.
    González Cao M; Malvehy J; Martí R; Conill C; Sánchez M; Martín M; Carrera C; Herrero J; Gascón P; Mellado B; Castel T; Puig S
    Melanoma Res; 2006 Feb; 16(1):59-64. PubMed ID: 16432457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical results using biochemotherapy as a standard of care in advanced melanoma.
    Chapman PB; Panageas KS; Williams L; Wolchok JD; Livingston PO; Quinn C; Hwu WJ
    Melanoma Res; 2002 Aug; 12(4):381-7. PubMed ID: 12170188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy.
    O'Day SJ; Boasberg PD; Piro L; Kristedja TS; Wang HJ; Martin M; Deck R; Ames P; Shinn K; Kim H; Fournier P; Gammon G
    Clin Cancer Res; 2002 Sep; 8(9):2775-81. PubMed ID: 12231516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicentre, open, noncomparative Phase II trial to evaluate the efficacy and tolerability of fotemustine, cisplatin, alpha-interferon and interleukin-2 in advanced melanoma patients.
    Ridolfi L; Fiorentini G; Guida M; Michiara M; Freschi A; Aitini E; Ballardini M; Bichisao E; Ridolfi R;
    Melanoma Res; 2009 Apr; 19(2):100-5. PubMed ID: 19262411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interleukin-2-based biochemotherapy for patients with stage IV melanoma: long-term survivors outside a clinical trial setting.
    Hess V; Herrmann R; Veelken H; Schwabe M
    Oncology; 2007; 73(1-2):33-40. PubMed ID: 18332650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
    Flaherty LE
    Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
    O'Day SJ; Atkins MB; Boasberg P; Wang HJ; Thompson JA; Anderson CM; Gonzalez R; Lutzky J; Amatruda T; Hersh EM; Weber JS
    J Clin Oncol; 2009 Dec; 27(36):6207-12. PubMed ID: 19917850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II trial of BCDT [carmustine (BCNU), cisplatin, dacarbazine (DTIC) and tamoxifen] with or without interferon alpha (IFN-alpha) and interleukin (IL-2) in patients with metastatic melanoma.
    Johnston SR; Constenla DO; Moore J; Atkinson H; A'Hern RP; Dadian G; Riches PG; Gore ME
    Br J Cancer; 1998 Apr; 77(8):1280-6. PubMed ID: 9579834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 558.